Andreas Kovar
Overview
Explore the profile of Andreas Kovar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
370
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Frank T, Kovar A, Strougo A, Vage C, Teuscher N, Wong N
J Pharmacol Exp Ther
. 2023 May;
386(2):143-155.
PMID: 37164370
Sutimlimab, a humanized monoclonal antibody targeting the classic complement pathway, is approved in the United States, Japan, and the European Union for the treatment of hemolytic anemia in adults with...
2.
Frank T, Gastine S, Lindauer K, Speth H, Strougo A, Kovar A
CPT Pharmacometrics Syst Pharmacol
. 2021 Sep;
10(11):1310-1322.
PMID: 34478613
Writing population analysis reports that fulfilling the specifications of submission readiness is a time-consuming process and prone to human error. Thus, there is a need to streamline the creation of...
3.
Lippert J, Burghaus R, Edginton A, Frechen S, Karlsson M, Kovar A, et al.
CPT Pharmacometrics Syst Pharmacol
. 2019 Nov;
8(12):878-882.
PMID: 31671256
No abstract available.
4.
Becker A, von Richter O, Kovar A, Scheible H, van Lier J, Johne A
J Clin Pharmacol
. 2015 Feb;
55(7):815-24.
PMID: 25683324
Cilengitide (EMD 121974, manufactured by Merck KGaA, Darmstadt, Germany) is an αv-integrin receptor antagonist showing high affinity for αvβ3 and αvβ5.This study determined the mass balance of cilengitide in healthy...
5.
Zuhlsdorf M, Bhattaram V, Campioni M, Krosser S, Derendorf H, Kovar A
J Clin Pharmacol
. 2014 Jun;
54(12):1391-9.
PMID: 24911832
Cilengitide is an αvβ3/αvβ5-integrin inhibitor investigated as an anticancer agent. This study aimed to develop a cilengitide population pharmacokinetic model using nonlinear mixed-effects modeling of 136 adult patients with advanced...
6.
Uhl W, Zuhlsdorf M, Koernicke T, Forssmann U, Kovar A
Invest New Drugs
. 2013 Nov;
32(2):347-54.
PMID: 24242902
Purpose: We evaluated the safety, tolerability, and pharmacokinetics (PK) of EMD 525797 (DI17E6), a humanized monoclonal antibody targeting αv-integrins, in healthy subjects. Methods: In this first-in-human, double-blind, placebo-controlled, randomized Phase...
7.
Budha N, Kovar A, Meibohm B
AAPS J
. 2011 Oct;
13(4):650-61.
PMID: 22005901
Prolonged time delay in response to drug action is a common feature of hematological responses to pharmacotherapy such as erythropoiesis. The objective of this study was to compare the performance...
8.
Liedert B, Forssmann U, Wolna P, Golob M, Kovar A
BMC Clin Pharmacol
. 2010 Oct;
10:14.
PMID: 20961422
Background: Somatropin is recombinant human growth hormone (GH) used for the treatment of growth failure in children and GH deficiency in adults. Two concentrations of a liquid formulation have been...
9.
Kuester K, Kovar A, Lupfert C, Brockhaus B, Kloft C
Clin Pharmacokinet
. 2009 Aug;
48(7):477-87.
PMID: 19691369
Objectives: A developed population pharmacokinetic model of the humanized monoclonal antibody (mAb) matuzumab was evaluated by external evaluation. Based on the estimates of the final model, simulations of different dosing...
10.
Ribas A, Kirkwood J, Atkins M, Whiteside T, Gooding W, Kovar A, et al.
J Transl Med
. 2009 Jul;
7:68.
PMID: 19640287
Background: To explore the biological activity of EMD 273063 (hu14.18-IL2), a humanized anti-GD2 monoclonal antibody fused to interleukin-2 (IL2), in patients with unresectable, stage IV cutaneous melanoma as measured by...